StemSight is a Finnish biotechnology company developing off-the-shelf regenerative cell therapies for severe corneal blindness. Its technology combines corneal cells manufactured from induced pluripotent stem cells with functional biomaterials for tissue regeneration and cell delivery. Its first program targets limbal stem cell deficiency; the company is advancing preclinical studies and manufacturing toward clinical development, and aims to reduce reliance on donated corneal tissue.
